The prognostic significance of pre-operative vs. prechemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer: A gynecologic oncology group study

Early Stage ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Ca 125 ◽

Oncology Group ◽

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.073 ◽

2010 ◽

Vol 116 (3) ◽

pp. 301-306 ◽

Cited By ~ 75

Author(s):

John K. Chan ◽

Chunqiao Tian ◽

Gini F. Fleming ◽

Bradley J. Monk ◽

Thomas J. Herzog ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Potential Benefit ◽

Early Stage ◽

Gynecologic Oncology ◽

Exploratory Analysis ◽

Oncology Group ◽

The pattern of CA-125 normalization during chemotherapy predicts for recurrence and survival in patients with high-risk early-stage ovarian cancer: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.019 ◽

2010 ◽

Vol 116 (3) ◽

pp. 596

Author(s):

J. Chan ◽

C. Tian ◽

K. Yang ◽

J. Kesterson ◽

D. Kapp ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Early Stage ◽

Gynecologic Oncology ◽

Ca 125 ◽

Oncology Group ◽

Oncology Group Study ◽

Early Stage Ovarian Cancer

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

Yearbook of Medicine ◽

10.1016/s0084-3873(10)79915-6 ◽

2010 ◽

Vol 2010 ◽

pp. 166-167

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Potential Benefit ◽

Early Stage ◽

Gynecologic Oncology ◽

Exploratory Analysis ◽

Oncology Group ◽

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79514-2 ◽

2010 ◽

Vol 2010 ◽

pp. 59-60

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Potential Benefit ◽

Early Stage ◽

Gynecologic Oncology ◽

Exploratory Analysis ◽

Oncology Group ◽

Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.074 ◽

2010 ◽

Vol 116 (3) ◽

pp. 307-311 ◽

Cited By ~ 31

Author(s):

John K. Chan ◽

Chunqiao Tian ◽

Deanna Teoh ◽

Bradley J. Monk ◽

Thomas Herzog ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Early Stage ◽

Gynecologic Oncology ◽

Oncology Group ◽

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.02.014 ◽

2006 ◽

Vol 101 (3) ◽

pp. 390-397 ◽

Cited By ~ 26

Author(s):

Angeles Alvarez Secord ◽

Paula S. Lee ◽

Kathleen M. Darcy ◽

Laura J. Havrilesky ◽

Lisa A. Grace ◽

...

Keyword(s):

Ovarian Cancer ◽

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.035 ◽

2012 ◽

Vol 124 (3) ◽

pp. 563-568 ◽

Cited By ~ 7

Author(s):

Leslie M. Randall ◽

Michael W. Sill ◽

Robert A. Burger ◽

Bradley J. Monk ◽

Barbara Buening ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Predictive Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Ca 125 ◽

Oncology Group ◽

Peritoneal Cancer

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.05.033 ◽

2004 ◽

Vol 94 (2) ◽

pp. 368-374 ◽

Cited By ~ 40

Author(s):

David H Moore ◽

James T Kauderer ◽

Jeffrey Bell ◽

John P Curtin ◽

Linda Van Le

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Alternative Treatments ◽

Oncology Group Study ◽

Factors Influencing

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression